Home > Multinationals > Johnson & Johnson

Claimed by owner • Last Update Apr 28, 2026 • Suggest Edits • Claim Profile

Claimed by owner

Johnson & Johnson

Healthcare • United States

PUBLIC on NYSE on Jan, 1978

Johnson & Johnson

Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock

Johnson & Johnson (JNJ): Growth Engine at a Value Price

How to Play J&J Stock Post a Beat-and-Raise Performance in Q1

J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag

Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

Dow Jones Futures Rise, Oil Prices Fall Below $100; Trump To Speak To Nation On Iran War

Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?

#Acquisition #Product Stage

Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?

#Acquisition #Investment

J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital

Sector Update: Health Care Stocks Lower in Friday Afternoon Trading

Sector Update: Health Care Stocks Edge Higher Late Afternoon

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

#Product Stage #Customers

Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

#Management Changes

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

#Management Changes

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026

JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus

J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

#Product Stage #Acquisition #FDA approved/pending approval

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

#Product Stage #Customers

Commentary: Trump’s trade war is hurting most sectors of the economy

#Customers

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

US-EU trade deal impacts on pharma industry more 'manageable' than expected

TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

#Product Stage #Partners #Customers

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

#Product Stage #Partners #Customers

J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?

#Product Stage #Acquired-by

Pharma giant adds Israel to list of Middle East markets after omission raises questions

#Customers

Bank Bonds That Cut Risk Draw Ares and Blackstone: Credit Weekly

#Investment #Partners

J&J Weighs Third Bankruptcy Try to Settle Baby Powder Suits

J&J to close Tel Hashomer blood bank operations

#Layoffs

J&J leads $28m round in Israel's V-Wave

#Investment #Management Changes #Expand

Johnson & Johnson to establish new biotechnology incubator in Israel

#Partners #Investment

Omrix obtains FDA approval for fibrin sealant

#Customers

Johnson & Johnson Inc engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company's segments include consumer, pharmaceutical, and medical devices. The company's primary focus is on products related to human health and wellbeing.

In Israel, Johnson & Johnson has four sub-companies. The company's operations in Israel span research and development, as well as commercial activities in the healthcare sector.

Founded

1886

In Israel Since

9/1997

Employees Worldwide

50,000+

Employees In Israel

201-500

Market Cap

$498.6B

Market Cap Update

1/2026

Country

United States

News

(43)

Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock

Johnson & Johnson (JNJ): Growth Engine at a Value Price

How to Play J&J Stock Post a Beat-and-Raise Performance in Q1

J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag

Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

Dow Jones Futures Rise, Oil Prices Fall Below $100; Trump To Speak To Nation On Iran War

Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?

#Acquisition #Product Stage

Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?

#Acquisition #Investment

J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms Capital

Sector Update: Health Care Stocks Lower in Friday Afternoon Trading

Sector Update: Health Care Stocks Edge Higher Late Afternoon

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

#Product Stage #Customers

Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

#Management Changes

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

#Management Changes

Johnson & Johnson Targets Accelerated Growth Across Segments in 2026

JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus

J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

#Product Stage #Acquisition #FDA approved/pending approval

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

#Product Stage #Customers

Commentary: Trump’s trade war is hurting most sectors of the economy